Studies have shown that the use of nutritional supplements, as well as other types of alternative therapy, has increased as patients seek less toxic and more holistic approaches to health. However, a new study conducted by BCRF investigator Christine Ambrosone, PhD, Professor and Chair of the Department of Cancer Prevention and Control at Roswell Park Comprehensive Cancer Center in Buffalo, NY, has revealed new evidence supporting recommendations against the use of one type of alternative therapy—antioxidant supplements—during chemotherapy.
Chemotherapy is a standard component of most cancer treatments and is very effective at killing cancer cells. A number of chemotherapy agents work through the generation of inflammatory molecules called reactive oxygen species (ROS) that are toxic to cells. Antioxidants reduce ROS, which is a good thing—but not when the goal is to kill cells. There has been concern that supplemental antioxidants, which patients may take for their purported health benefits, can counter the effect of chemotherapy by reducing ROS.
The study, called Diet, Exercise, Lifestyle and Cancer Prognosis (DELCaP), was conducted within a clinical trial led by SWOG Cancer Research Network (S0221) to compare chemotherapy dosing regimens in newly diagnosed patients with high-risk breast cancer. Patients received the same drugs but at different dosing regimens to see if one dosing schedule was more effective than the other.
Patients participating in the DELCaP study were asked to complete a questionnaire about supplement use, diet, exercise, and other lifestyle factors at the beginning of the study and after completion of chemotherapy. 1,600 patients were enrolled; the study, published in the Journal of Clinical Oncology, included 1,134 patients who completed both surveys.
The key findings: Continuous antioxidants use, but not multivitamin use, was associated with worse outcomes.
Other studies have looked at supplement use and cancer outcomes, but none have studied supplement use specifically during chemotherapy. This is the first study to assess supplement use before, during, and after chemotherapy with a median follow-up of over 8 years. Another strength of Dr. Ambrosone’s study is that it was conducted in the context of a clinical trial where all patients received the same drugs.
The researchers were somewhat surprised by some of the findings. They hoped that a clinical trial of more than 3,000 patients would be an excellent opportunity to assess the effects of supplement use on patient outcomes. What they found, however, was that the number of patients taking antioxidants was much lower than trends would predict. This hampered their ability to assess the effects of individual antioxidants or to draw firm conclusions.
While there was not enough data to assess individual antioxidants, Dr. Ambrosone’s team found that supplemental vitamin B-12 before or during chemotherapy was strongly associated with worse outcome. The same was true for supplemental iron during chemotherapy.
What’s next? This study was observational in nature and was not designed to determine causation (whether supplement use is the reason some patients had worse outcomes). But it does support a recommendation of caution with supplements, particularly antioxidants, during chemotherapy. Dr. Ambrosone is collaborating with colleagues at Kaiser Permanente Northern California on a prospective study of more than 4,000 women with breast cancer, which collects data on habits at multiple timepoints. This large study may shed some additional light on the effects of dietary supplements on treatment outcomes.
Please remember BCRF in your will planning. Learn More
Breast Cancer Research Foundation28 West 44th Street, Suite 609, New York, NY 10036
General Office: 646-497-2600 | Toll Free: email@example.com | BCRF is a 501 (c)(3) | EIN: 13-3727250